SlideShare una empresa de Scribd logo
1 de 33
EVALUATION OF THERAPEUTIC RESPONSE OF METFORMIN HCl AND ITS RATIONALE COMBINATIONS ON GLYCEMIC VALUE IN DIABETICS   C SUJANI B UMA MAHESH B SUNIL GAVASKAR D SIVA SANKAR K V  HIMA BINDU K V GOPINATH  &  B  PUSHPA KUMARI DEPARTMENT OF PHARMACOLOGY   SRI PADMAVATHI SCHOOL OF PHARMACY TIRUPATI - 517 503  (A.P.) INDIA
Aim ,[object Object]
Objectives        ,[object Object],[object Object],[object Object],[object Object],[object Object]
Plan of Work   Design of Study   Retrospective  and prospective   Study Site   T.T.D Central hospital, SVIMS   Study Period   October, 06 to March, 2007
Inclusive Criteria   ,[object Object],[object Object],[object Object],[object Object]
Exclusive Criteria   ,[object Object],[object Object],[object Object],[object Object]
Plan of Work ,[object Object],[object Object],[object Object],[object Object],[object Object]
Plan of Work ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Plan of Work ,[object Object],[object Object],[object Object],[object Object]
Plan of Work ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Data on  diseases
Demographic data based on sex (n=320)
Demographic data based on age (n=320)
Demographic data based on education  (n=320)
Demographic data based on Occupation
Demographic data based on Smoking  (n=320)
Demographic data based on Alcohol  social habit  (n=320)
Demographic data based on Mean  +   SD   (n=206)
Causes of diabetes  (n=320)
Risk factor - BMI
Demographic data based on treatment profile   (n=210)
Effect of anti-diabetic drug(s) 0n glycemic value   (%change)
Percentage change in glycemic value of Metformin HCl
Percentage change in glycemic value of Metformin + Glibenclamide treatment
Percentage change in glycemic value of Metformin + Glipizide treatment
Percentage change in glycemic value of Met + Pioz + Acarbose treatment
Therapeutic response of anti-diabetic drug(s) on glycemic value
Adverse Drug Reactions of Anti-Diabetic Drugs  (n=320)
Data on diabetic complications
Conclusion ,[object Object],[object Object],[object Object]
Conclusion ,[object Object],[object Object],[object Object],[object Object]
Sincere Thanks  ,[object Object],[object Object],[object Object],[object Object]
 

Más contenido relacionado

La actualidad más candente

Polypharm presentation
Polypharm presentationPolypharm presentation
Polypharm presentation
Lisa Tripp
 
Falls prevention and the role of the pharmacist
Falls prevention and the role of the pharmacistFalls prevention and the role of the pharmacist
Falls prevention and the role of the pharmacist
Richard Harris
 
Phase 0 & i clinical trial designing,conduct &challenges
Phase 0 & i clinical trial designing,conduct &challengesPhase 0 & i clinical trial designing,conduct &challenges
Phase 0 & i clinical trial designing,conduct &challenges
DrSatyabrataSahoo
 

La actualidad más candente (20)

Getting the most out of your scpp practice review l. postnikoff
Getting the most out of your scpp practice review l. postnikoffGetting the most out of your scpp practice review l. postnikoff
Getting the most out of your scpp practice review l. postnikoff
 
Detection and monitoring of ADRs
Detection and monitoring of ADRsDetection and monitoring of ADRs
Detection and monitoring of ADRs
 
Pharmaceutical Care of Patients with Infections | 29/03/2010
Pharmaceutical Care of Patients with Infections | 29/03/2010Pharmaceutical Care of Patients with Infections | 29/03/2010
Pharmaceutical Care of Patients with Infections | 29/03/2010
 
Essential drug concept and rational use of medicines
Essential drug concept and rational use of medicinesEssential drug concept and rational use of medicines
Essential drug concept and rational use of medicines
 
Thesis_PhD_Improving medication safety in the elderly
Thesis_PhD_Improving medication safety in the elderlyThesis_PhD_Improving medication safety in the elderly
Thesis_PhD_Improving medication safety in the elderly
 
Personalised Medicine- Future of Medicine.
Personalised Medicine- Future of Medicine.Personalised Medicine- Future of Medicine.
Personalised Medicine- Future of Medicine.
 
Drug Utilization Studies
Drug Utilization StudiesDrug Utilization Studies
Drug Utilization Studies
 
Introduction Clinical Pharmacy Practices
Introduction Clinical Pharmacy PracticesIntroduction Clinical Pharmacy Practices
Introduction Clinical Pharmacy Practices
 
Patient compliance and follow up issues
Patient compliance and follow up issuesPatient compliance and follow up issues
Patient compliance and follow up issues
 
Zeshan Ahmed Managing polypharmacy
Zeshan Ahmed Managing polypharmacyZeshan Ahmed Managing polypharmacy
Zeshan Ahmed Managing polypharmacy
 
Polypharm presentation
Polypharm presentationPolypharm presentation
Polypharm presentation
 
How to fill adr reporitng form
How to fill adr reporitng formHow to fill adr reporitng form
How to fill adr reporitng form
 
Falls prevention and the role of the pharmacist
Falls prevention and the role of the pharmacistFalls prevention and the role of the pharmacist
Falls prevention and the role of the pharmacist
 
Ch 2 basic concepts in pharmacoepidemiology (10 hrs)
Ch 2 basic concepts in pharmacoepidemiology (10 hrs)Ch 2 basic concepts in pharmacoepidemiology (10 hrs)
Ch 2 basic concepts in pharmacoepidemiology (10 hrs)
 
Clinical trial for BPH
Clinical trial for BPHClinical trial for BPH
Clinical trial for BPH
 
Detection, reporting and monitoring of ad rs final ppt
Detection, reporting and monitoring of ad rs final pptDetection, reporting and monitoring of ad rs final ppt
Detection, reporting and monitoring of ad rs final ppt
 
13 vol.-4-issue-2-feb-2013-ijpsr-ra-2131-paper-13 (1)
13 vol.-4-issue-2-feb-2013-ijpsr-ra-2131-paper-13 (1)13 vol.-4-issue-2-feb-2013-ijpsr-ra-2131-paper-13 (1)
13 vol.-4-issue-2-feb-2013-ijpsr-ra-2131-paper-13 (1)
 
Drug utilisation studies
Drug utilisation studiesDrug utilisation studies
Drug utilisation studies
 
Phase 0 & i clinical trial designing,conduct &challenges
Phase 0 & i clinical trial designing,conduct &challengesPhase 0 & i clinical trial designing,conduct &challenges
Phase 0 & i clinical trial designing,conduct &challenges
 
PVPI _ A Cost Effective Programme For Patients
PVPI _ A Cost Effective Programme For Patients PVPI _ A Cost Effective Programme For Patients
PVPI _ A Cost Effective Programme For Patients
 

Destacado

Diabetic Education Guide
Diabetic Education GuideDiabetic Education Guide
Diabetic Education Guide
Carolyn Meyer
 
26.09 metformain as a antiaterosceoti
26.09 metformain as a antiaterosceoti26.09 metformain as a antiaterosceoti
26.09 metformain as a antiaterosceoti
Rajeev Agarwala
 
Ueda2015 metformin xr, a rational destination in type2 dr.mesbah kamel.pptx
Ueda2015 metformin xr, a rational destination in type2 dr.mesbah kamel.pptxUeda2015 metformin xr, a rational destination in type2 dr.mesbah kamel.pptx
Ueda2015 metformin xr, a rational destination in type2 dr.mesbah kamel.pptx
ueda2015
 

Destacado (20)

Metformin is a revolutionary anti diabetic drug
Metformin is a revolutionary anti diabetic drugMetformin is a revolutionary anti diabetic drug
Metformin is a revolutionary anti diabetic drug
 
Effect of ethanolic extract of piper cubeba linn fruits on activity of piogli...
Effect of ethanolic extract of piper cubeba linn fruits on activity of piogli...Effect of ethanolic extract of piper cubeba linn fruits on activity of piogli...
Effect of ethanolic extract of piper cubeba linn fruits on activity of piogli...
 
Med Basics: Metformin
Med Basics: MetforminMed Basics: Metformin
Med Basics: Metformin
 
Metformin hydrochloride
Metformin hydrochlorideMetformin hydrochloride
Metformin hydrochloride
 
Metformin PowerPoint
Metformin PowerPointMetformin PowerPoint
Metformin PowerPoint
 
Metformin A Pharmacological Preespective
Metformin A Pharmacological PreespectiveMetformin A Pharmacological Preespective
Metformin A Pharmacological Preespective
 
Metformin
MetforminMetformin
Metformin
 
Metformin presentation sigma xi
Metformin presentation sigma xiMetformin presentation sigma xi
Metformin presentation sigma xi
 
Diabetic Education by Angela Reynolds
Diabetic Education by Angela ReynoldsDiabetic Education by Angela Reynolds
Diabetic Education by Angela Reynolds
 
Diabetic Education Guide
Diabetic Education GuideDiabetic Education Guide
Diabetic Education Guide
 
26.09 metformain as a antiaterosceoti
26.09 metformain as a antiaterosceoti26.09 metformain as a antiaterosceoti
26.09 metformain as a antiaterosceoti
 
Monitoring the effectiveness of risk minimisation in patients treated with pi...
Monitoring the effectiveness of risk minimisation in patients treated with pi...Monitoring the effectiveness of risk minimisation in patients treated with pi...
Monitoring the effectiveness of risk minimisation in patients treated with pi...
 
Ueda2015 metformin xr, a rational destination in type2 dr.mesbah kamel.pptx
Ueda2015 metformin xr, a rational destination in type2 dr.mesbah kamel.pptxUeda2015 metformin xr, a rational destination in type2 dr.mesbah kamel.pptx
Ueda2015 metformin xr, a rational destination in type2 dr.mesbah kamel.pptx
 
1362397244 patient self care program prev.ulcer
1362397244 patient self care program prev.ulcer1362397244 patient self care program prev.ulcer
1362397244 patient self care program prev.ulcer
 
Generic Metformin Tablets for Treatment of Type 2 Diabetes (Non-Insulin Dep...
Generic Metformin Tablets for Treatment  of Type 2 Diabetes (Non-Insulin  Dep...Generic Metformin Tablets for Treatment  of Type 2 Diabetes (Non-Insulin  Dep...
Generic Metformin Tablets for Treatment of Type 2 Diabetes (Non-Insulin Dep...
 
X ray fluorescence (X R F)
X ray fluorescence (X R F)X ray fluorescence (X R F)
X ray fluorescence (X R F)
 
Ueda2016 symposium - metformin ® xr - mohamed mashaheet
Ueda2016 symposium - metformin ® xr - mohamed mashaheetUeda2016 symposium - metformin ® xr - mohamed mashaheet
Ueda2016 symposium - metformin ® xr - mohamed mashaheet
 
Pioglitazone
PioglitazonePioglitazone
Pioglitazone
 
Cancer and immunology
Cancer and immunologyCancer and immunology
Cancer and immunology
 
Ayurveda pharmacopoeia
Ayurveda pharmacopoeiaAyurveda pharmacopoeia
Ayurveda pharmacopoeia
 

Similar a Diabetic Presentation Corrected

Agreement between Claims-based and Self-reported Adherence Measures in Patien...
Agreement between Claims-based and Self-reported Adherence Measures in Patien...Agreement between Claims-based and Self-reported Adherence Measures in Patien...
Agreement between Claims-based and Self-reported Adherence Measures in Patien...
dylanturner22
 
Study on Role of Clinical Pharmacist in counselling of Diabetic Patients
Study on Role of Clinical Pharmacist in counselling of Diabetic PatientsStudy on Role of Clinical Pharmacist in counselling of Diabetic Patients
Study on Role of Clinical Pharmacist in counselling of Diabetic Patients
BRNSSPublicationHubI
 
Diabetic nursing visits for better A1C control in patients Discussion.pdf
Diabetic nursing visits for better A1C control in patients Discussion.pdfDiabetic nursing visits for better A1C control in patients Discussion.pdf
Diabetic nursing visits for better A1C control in patients Discussion.pdf
sdfghj21
 
Early treatment revisions by addition or switch for type 2 diabetes- impact o...
Early treatment revisions by addition or switch for type 2 diabetes- impact o...Early treatment revisions by addition or switch for type 2 diabetes- impact o...
Early treatment revisions by addition or switch for type 2 diabetes- impact o...
Vishal Saundankar MS, PGDMM, BS (PHARMACY)
 
Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...
Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...
Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...
Vishal Saundankar MS, PGDMM, BS (PHARMACY)
 
1601Rev Bras Enferm. 2019;72(6)1601-8. httpdx.doi.org10.1.docx
1601Rev Bras Enferm. 2019;72(6)1601-8. httpdx.doi.org10.1.docx1601Rev Bras Enferm. 2019;72(6)1601-8. httpdx.doi.org10.1.docx
1601Rev Bras Enferm. 2019;72(6)1601-8. httpdx.doi.org10.1.docx
aulasnilda
 

Similar a Diabetic Presentation Corrected (20)

EVALUATION OF GLYCEMIC RESPONSE OF ADDITION OF PIOGLITAZONE TO GLIBENCLAMIDE...
 EVALUATION OF GLYCEMIC RESPONSE OF ADDITION OF PIOGLITAZONE TO GLIBENCLAMIDE... EVALUATION OF GLYCEMIC RESPONSE OF ADDITION OF PIOGLITAZONE TO GLIBENCLAMIDE...
EVALUATION OF GLYCEMIC RESPONSE OF ADDITION OF PIOGLITAZONE TO GLIBENCLAMIDE...
 
ISPOR
ISPORISPOR
ISPOR
 
Diabetes MedInsights
Diabetes MedInsightsDiabetes MedInsights
Diabetes MedInsights
 
ISPOR podium presentation
ISPOR podium presentationISPOR podium presentation
ISPOR podium presentation
 
Agreement between Claims-based and Self-reported Adherence Measures in Patien...
Agreement between Claims-based and Self-reported Adherence Measures in Patien...Agreement between Claims-based and Self-reported Adherence Measures in Patien...
Agreement between Claims-based and Self-reported Adherence Measures in Patien...
 
Study on Role of Clinical Pharmacist in counselling of Diabetic Patients
Study on Role of Clinical Pharmacist in counselling of Diabetic PatientsStudy on Role of Clinical Pharmacist in counselling of Diabetic Patients
Study on Role of Clinical Pharmacist in counselling of Diabetic Patients
 
protocol ppt
protocol pptprotocol ppt
protocol ppt
 
Diabetic nursing visits for better A1C control in patients Discussion.pdf
Diabetic nursing visits for better A1C control in patients Discussion.pdfDiabetic nursing visits for better A1C control in patients Discussion.pdf
Diabetic nursing visits for better A1C control in patients Discussion.pdf
 
Early treatment revisions by addition or switch for type 2 diabetes- impact o...
Early treatment revisions by addition or switch for type 2 diabetes- impact o...Early treatment revisions by addition or switch for type 2 diabetes- impact o...
Early treatment revisions by addition or switch for type 2 diabetes- impact o...
 
Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...
Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...
Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...
 
Role of pharmacist in managing diabetes mellitus
Role of pharmacist in managing diabetes mellitusRole of pharmacist in managing diabetes mellitus
Role of pharmacist in managing diabetes mellitus
 
1601Rev Bras Enferm. 2019;72(6)1601-8. httpdx.doi.org10.1.docx
1601Rev Bras Enferm. 2019;72(6)1601-8. httpdx.doi.org10.1.docx1601Rev Bras Enferm. 2019;72(6)1601-8. httpdx.doi.org10.1.docx
1601Rev Bras Enferm. 2019;72(6)1601-8. httpdx.doi.org10.1.docx
 
Futuro en el tratamiento de la DM2
Futuro en el tratamiento de la DM2Futuro en el tratamiento de la DM2
Futuro en el tratamiento de la DM2
 
Dandona Diabetes
Dandona DiabetesDandona Diabetes
Dandona Diabetes
 
Designing Causal Inference Studies Using Real-World Data
Designing Causal Inference Studies Using Real-World DataDesigning Causal Inference Studies Using Real-World Data
Designing Causal Inference Studies Using Real-World Data
 
Managing Type 2 Diabetes
Managing Type 2 DiabetesManaging Type 2 Diabetes
Managing Type 2 Diabetes
 
After Metformin What- Indian Scenario
After Metformin What- Indian ScenarioAfter Metformin What- Indian Scenario
After Metformin What- Indian Scenario
 
Poster
PosterPoster
Poster
 
Paper 5
Paper 5Paper 5
Paper 5
 
Saxagliptin eficacia
Saxagliptin eficaciaSaxagliptin eficacia
Saxagliptin eficacia
 

Más de Nani Karnam Vinayakam

Nano technology and its releavance to drug designing 08072013
Nano technology and its releavance to drug designing 08072013Nano technology and its releavance to drug designing 08072013
Nano technology and its releavance to drug designing 08072013
Nani Karnam Vinayakam
 
Experimental and clinical validation of classical and proproetary ayurvedic f...
Experimental and clinical validation of classical and proproetary ayurvedic f...Experimental and clinical validation of classical and proproetary ayurvedic f...
Experimental and clinical validation of classical and proproetary ayurvedic f...
Nani Karnam Vinayakam
 

Más de Nani Karnam Vinayakam (17)

International_Day_Against_Drug_Abuse__Illicit_Trafficking.ppt
International_Day_Against_Drug_Abuse__Illicit_Trafficking.pptInternational_Day_Against_Drug_Abuse__Illicit_Trafficking.ppt
International_Day_Against_Drug_Abuse__Illicit_Trafficking.ppt
 
Pharmacy always trusted for your health.ppt1234
Pharmacy  always trusted for your health.ppt1234Pharmacy  always trusted for your health.ppt1234
Pharmacy always trusted for your health.ppt1234
 
Practical Approach of safe Disposal of Hospital Waste Management
Practical Approach of safe Disposal of Hospital Waste ManagementPractical Approach of safe Disposal of Hospital Waste Management
Practical Approach of safe Disposal of Hospital Waste Management
 
Pharmacy practice – a spiritual transformation
Pharmacy practice – a spiritual transformationPharmacy practice – a spiritual transformation
Pharmacy practice – a spiritual transformation
 
Scanning Electron Microscope- Energy - Dispersive X -Ray Microanalysis (Sem E...
Scanning Electron Microscope- Energy - Dispersive X -Ray Microanalysis (Sem E...Scanning Electron Microscope- Energy - Dispersive X -Ray Microanalysis (Sem E...
Scanning Electron Microscope- Energy - Dispersive X -Ray Microanalysis (Sem E...
 
Pharmacy “it’s even more than you can imagine.”
Pharmacy “it’s even more than you can imagine.”Pharmacy “it’s even more than you can imagine.”
Pharmacy “it’s even more than you can imagine.”
 
Manufacture of sterile and nonsterile products
Manufacture of sterile and nonsterile productsManufacture of sterile and nonsterile products
Manufacture of sterile and nonsterile products
 
Asthma a clinical review and its management
Asthma  a clinical review and its managementAsthma  a clinical review and its management
Asthma a clinical review and its management
 
Nano technology and its releavance to drug designing 08072013
Nano technology and its releavance to drug designing 08072013Nano technology and its releavance to drug designing 08072013
Nano technology and its releavance to drug designing 08072013
 
New and traditional ayurvedic dosage forms
New and traditional ayurvedic dosage formsNew and traditional ayurvedic dosage forms
New and traditional ayurvedic dosage forms
 
Analytical, toxicity, experimental and clinical validation of ayurvedic formu...
Analytical, toxicity, experimental and clinical validation of ayurvedic formu...Analytical, toxicity, experimental and clinical validation of ayurvedic formu...
Analytical, toxicity, experimental and clinical validation of ayurvedic formu...
 
X ray diffraction
X ray diffractionX ray diffraction
X ray diffraction
 
Thin Layer Chromatography and HighPerformance Thin Layer chromatography
Thin Layer Chromatography and HighPerformance Thin Layer chromatographyThin Layer Chromatography and HighPerformance Thin Layer chromatography
Thin Layer Chromatography and HighPerformance Thin Layer chromatography
 
Gas chromatography
Gas chromatographyGas chromatography
Gas chromatography
 
Experimental and clinical validation of classical and proproetary ayurvedic f...
Experimental and clinical validation of classical and proproetary ayurvedic f...Experimental and clinical validation of classical and proproetary ayurvedic f...
Experimental and clinical validation of classical and proproetary ayurvedic f...
 
Nano technology and its releavance to aushadha nirman 08072013
Nano technology and its releavance to aushadha   nirman 08072013Nano technology and its releavance to aushadha   nirman 08072013
Nano technology and its releavance to aushadha nirman 08072013
 
Toxic studies
Toxic studiesToxic studies
Toxic studies
 

Diabetic Presentation Corrected